SEC Form 3
FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 09/01/2022 | 3. Issuer Name and Ticker or Trading Symbol PRECISION BIOSCIENCES INC [ DTIL ] | |||||||||||||
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 1,902,474 | D | |
Common Stock | 237,959 | I | By Charitable Remainder Unitrust |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Buy) | (1) | 03/23/2027 | Common Stock | 23,422 | 1.18 | D | |
Employee Stock Option (Right to Buy) | (2) | 10/11/2028 | Common Stock | 46,845 | 11.98 | D | |
Employee Stock Option (Right to Buy) | (3) | 08/20/2030 | Common Stock | 35,786 | 5.83 | D | |
Employee Stock Option (Right to Buy) | (4) | 06/06/2031 | Common Stock | 25,118 | 11.34 | D | |
Restricted Stock Units | (5) | (5) | Common Stock | 9,744 | (6) | D | |
Employee Stock Option (Right to Buy) | (7) | 03/02/2032 | Common Stock | 74,197 | 4.08 | D | |
Restricted Stock Units | (8) | (8) | Common Stock | 46,720 | (6) | D |
Explanation of Responses: |
1. Stock options are fully vested as of the date of this report. |
2. The option vested as to 25% of the underlying shares on September 28, 2019 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
3. The option vested as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
4. The option vested as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
5. The restricted stock units ("RSUs") vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
6. The Reporting Person was granted RSUs, which each represents a contingent right to receive one share of the Company's Common Stock. |
7. The option vests as to 25% of the underlying shares on March 3, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
8. The RSUs vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. |
Remarks: |
Exhibit List: Exhibit 24 Power of Attorney |
/s/ Dario Scimeca, Attorney-in-Fact for J. Jefferson Smith | 09/09/2022 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |